How much does an insulin pump cost in Australia?
When researching diabetes technology, one of the most common questions is about affordability. How much does an insulin pump cost? The total expense can vary significantly depending on the type of pump, features, and how you access it. In general, this may include:
- The initial device or system cost
- Ongoing consumables (such as infusion sets or Pods)
- Optional continuous glucose monitoring (CGM) integration
Some people access them through private health insurance, while others may be eligible for government subsidies, which can help reduce overall costs.
How can I access an insulin pump?
To access a pump, you will need to discuss your eligibility with your diabetes healthcare team. Once you’ve consulted with your team and decided to move forward, they will support you by preparing all required documentation, including order forms, letters of support, and any necessary private health forms.
NDSS subsidy: what support is available?
The National Diabetes Services Scheme (NDSS) is an Australian Government program that helps people with diabetes access subsidised products and support services, including insulin pump consumables.
What does the NDSS cover?
For eligible individuals, the NDSS provides partial subsidies on insulin pump consumables, which may include:
- Infusion sets and reservoirs for traditional pumps
- Wearable Pods for tubeless systems
These consumables represent an ongoing cost, so NDSS support can help reduce the long-term insulin pump cost.
Who is eligible?
To access NDSS-subsidised insulin pump consumables, you must:
- Be living with type 1 diabetes
- Be registered with the NDSS
- Have an Insulin Pump Consumable Access Form completed and certified by a diabetes healthcare professional
How to access NDSS-subsidised consumables
Access typically involves:
- Consulting your diabetes healthcare team
- Completing the Insulin Pump Consumable Access Form
- Submitting the form to the NDSS
- Once approved, collecting consumables from an NDSS Access Point (usually a community pharmacy)
How NDSS affects overall insulin pump cost
The total expense will depend on how you access your system:
- With private health insurance: Your policy may cover the upfront cost of the pump, while consumables are subsidised through the NDSS.
- Without private health insurance: Some systems may be accessed via ongoing payment models, with NDSS subsidies helping reduce consumable costs.
Even with subsidies, a co-payment applies when collecting consumables through the NDSS, and usage limits may apply depending on the product.
The Omnipod® 5 difference: no lock-in subscription and pay-as-you go
In Australia, the Omnipod® 5 Automated Insulin Delivery (AID) System is currently the only tubeless insulin pump available and uses a different pricing model compared to other pumps.
Rather than requiring a large upfront cost, Omnipod 5 is designed as a pay-as-you-go system, where you purchase wearable Pods that are replaced every few days.
Costs typically include:
- An initial starter kit to begin using the system
- Ongoing Pod purchases (each Pod is worn for up to 3 days/72 hours)
- Optional continuous glucose monitoring (CGM) sensors, which are sold separately
Explore the cost of Omnipod® 5 in Australia
Get a clear breakdown of pricing, access pathways, and ongoing costs to see if Omnipod 5 is right for you.
Related Articles
Other topics
References and Disclaimers
1Insulin pump use in Australia (full publication; 8 Aug 2012 edition) (AIHW)
The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin. The Omnipod 5 System is intended to operate as an automated insulin delivery system when used with compatible Continuous Glucose Monitors (CGM). When in automated mode, the Omnipod 5 system is designed to assist people with type 1 diabetes in achieving glycaemic targets set by their healthcare providers. It is intended to modulate (increase, decrease or pause) insulin delivery to operate within predefined threshold values using current and predicted CGM values to maintain blood glucose at variable target glucose levels, thereby reducing glucose variability. This reduction in variability is intended to lead to a reduction in the frequency, severity, and duration of both hyperglycaemia and hypoglycaemia. The Omnipod 5 System can also operate in a manual mode that delivers insulin at set or manually adjusted rates.
The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with NovoLog®/NovoRapid®, Humalog® / Liprolog®, Admelog® / Insulin lispro Sanofi®, Trurapi® / Insulin aspart Sanofi®, and Kirsty® U-100 insulin. Warning: SmartAdjust™ technology should NOT be used by anyone under the age of 2 years old. SmartAdjust™ technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population. The Omnipod® 5 System is NOT recommended for people who are unable to monitor glucose as recommended by their healthcare provider, are unable to maintain contact with their healthcare provider, are unable to use the Omnipod® 5 System according to instructions, are taking hydroxyurea and using a Dexcom Sensor as it could lead to falsely elevated CGM values and result in over-delivery of insulin that can lead to severe hypoglycaemia, and do NOT have adequate hearing and/or vision to allow recognition of all functions of the Omnipod® 5 System, including alerts, alarms, and reminders. Device components including the Pod, CGM transmitter, and CGM sensor must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components.
Warning: DO NOT start to use the Omnipod® 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycaemia or hyperglycaemia.